1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Chi Sheng Pharma & Biotech Co., Ltd.

Chi Sheng Pharma & Biotech Co., Ltd.

TTPEX:4111
28.70
TWD
0.00
(0.00%)
3.13EPS
9.50P/E
1.79BMarket Cap
Nov 06Next Earn
Chi Sheng Pharma & Biotech Co., Ltd.
TPEX:4111
(Taipei Exchange)

Recent

price

28.70

P/E

ratio

9.50

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
11.12
11.13
14.48
15.39
15.76
15.58
16.11
17.46
16.17
17.1
16.37
17.09
19.1
17.73
19.48
23.01
23.7
Revenue per Share
0.52
0.41
1.22
1.6
1.22
0.65
1.22
1.37
0.71
1.21
0.99
1.35
2.57
1.15
1.85
2.75
3.15
Basic EPS, GAAP
-0.91
-0.28
1.15
-0.79
0.81
0.32
0.5
2.22
0.63
2.11
2.02
-2.11
1.82
-0.46
2.14
3.01
3.67
Free Cash Flow per Basic Share
0.24
0.25
0.29
0.34
0.44
0.37
0.57
0.76
0.76
0.57
0.95
0.95
0.95
1.14
0.95
0.95
- -
Dividend per Share
13.49
13.29
14.27
15.65
16.54
16.69
17.05
17.61
17.47
17.91
17.98
18.4
20.43
20.37
21.3
23.08
23.42
Book Value per Share
13.46
13.29
14.27
15.65
16.54
16.69
17.05
17.59
17.44
17.89
17.96
18.38
20.41
20.35
21.27
23.05
23.4
Tangible Book Value per Share
60
60
60
60
60
60
60
60
60
60
60
60
60
60
60
60
60
Basic Weighted Avg Shares
666
666
866
921
943
932
964
1,045
967
1,023
979
1,022
1,143
1,061
1,165
1,376
1,421
Sales/Revenue/Turnover
4.04
4.29
9.52
12.21
9.51
5.28
8.43
9.89
4.42
8.53
7.72
11.65
13.46
5.77
8.49
14.48
14.36
Operating Margin (%)
35
43
40
47
59
68
68
68
76
83
84
79
73
62
66
74
72
Depreciation Expense
31
25
73
96
73
39
73
82
42
72
59
81
154
69
111
164
189
Net Income, GAAP
3.65
16.1
14.58
17.73
23.19
30.56
21.34
22.15
29.65
25.51
27.37
18.27
- -
21.36
19.66
20.56
22.16
Effective Tax Rate (%)
4.68
3.72
8.43
10.38
7.74
4.19
7.55
7.83
4.37
7.08
6.04
7.9
13.47
6.47
9.49
11.93
13.31
Profit Margin (%)
245
275
265
196
212
206
216
264
265
332
391
205
376
353
412
464
434
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
9
7
7
2
1
7
6
5
LT Debt
807
795
854
936
990
999
1,020
1,054
1,045
1,072
1,076
1,101
1,222
1,219
1,275
1,381
1,401
Total Equity
5.46
2.46
7.09
8.05
5.67
2.84
5.28
6.52
2.38
5.14
4.39
7.37
- -
3.16
5.35
10.81
10.93
Return on Invested Capital (%)
6.56
2.67
7.51
8.52
6.13
3.31
6.08
6.73
3.41
5.8
4.8
6.24
- -
4.62
7.54
11.4
13.24
Return on Capital (%)
7.72
3.09
8.87
10.67
7.58
3.93
7.21
7.88
4.03
6.84
5.51
7.42
13.26
5.63
8.87
12.37
14.04
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
42
45
40
LT Borrowings
- -
- -
- -
LT Finance Leases
6
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
60
60
Market Capitalization
1,762
1,738
1,792

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
925
949
976
Cash, Cash Equivalents & STI
444
419
472
Accounts Receivable, Net
327
351
347
Inventories
103
104
103
Total Current Liabilities
461
419
542
Payables & Accruals
- -
- -
- -
ST Debt
42
45
40
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.35%
5.2%
8.33%
Free Cash Flow
-48.25%
-208.24%
40.7%
Net Income, GAAP
28.51%
36.29%
48.49%
Sales/Revenue/Turnover
4.29%
7.39%
18.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
267
283
284
331
1,165
2025
320
368
342
347
1,376
2026
357
375
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.39
0.34
0.34
0.78
1.85
2025
0.65
0.58
0.75
0.76
2.75
2026
0.9
0.74
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.95
2025
- -
- -
- -
- -
0.95
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Chi Sheng Pharma & Biotech Co., Ltd is a Taiwan-based pharmaceutical company principally engaged in the manufacture and distribution of medical medicines and equipment. The company offers a comprehensive portfolio of products including injections such as hemodialysis solutions, amino acid injections with electrolytes, vitamin injections, cephalosporin antibiotics, antihistamines, antipruritics, and ginkgo injections; oral solutions including antibiotics, cold syrups, and liquid antacids; externally applied medicines like contact lens solutions, normal saline wash, and povidone-iodine solutions; as well as consumptive products such as healthcare foods, skin care products, and cosmetics. It also provides medical devices and equipment. Chi Sheng Pharma & Biotech distributes its products domestically and internationally, with markets in Taiwan, Mainland China, and Southeast Asia. The company was originally founded as Chi Sheng Chemical Corporation in 1962 and rebranded to Chi Sheng Pharma & Biotech Co., Ltd to reflect its expanded focus on pharmaceutical and biotech segments. It holds ISO9001 and GMP food certifications, underscoring its adherence to quality standards. Chi Sheng maintains the largest market share in Taiwan for renal dialysate products, exceeding 50%. Recent operational highlights include continued expansion of its pharmaceutical product lines and strategic distribution growth into Southeast Asian markets, alongside ongoing development of parenteral-based medications. The company reported steady revenue growth in its pharmaceutical segment through to 2024 and remains active in medical innovation through collaborations within the biotechnology industry. Headquartered in Hsinchu Industrial Park, Taiwan, Chi Sheng Pharma & Biotech leverages its longstanding industry presence and robust manufacturing capabilities to serve healthcare providers and consumers. It targets medical institutions, pharmacies, and health-conscious consumers across its geographic footprint. The company's main operations emphasize injectable formulations, oral medicines, topical solutions, and healthcare consumables, positioning it as a key player in Taiwan's pharmaceutical and biotech sectors with expanding international reach. This description reflects Chi Sheng Pharma & Biotech's current product offerings, geographic markets, and recent strategic transformations within the last 1-2 years. The company continues to strengthen its market position by enhancing product innovation and broadening its service network while maintaining compliance with global standards.